RNAC
Cartesian Therapeutics, Inc.
Biotechnology
Market Cap$216M
5Y Perf.-89.5%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
RNAC vs KYMR vs IMVT vs ARQT vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
KYMR
Kymera Therapeutics, Inc.
Biotechnology
Market Cap$6.91B
5Y Perf.+165.3%
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.-19.8%
ARQT
Arcutis Biotherapeutics, Inc.
Biotechnology
Market Cap$2.58B
5Y Perf.-17.6%
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.50B
5Y Perf.+4.2%
RNAC vs KYMR vs IMVT vs ARQT vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNAC | KYMR | IMVT | ARQT | RCUS |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $216M | $6.91B | $5.53B | $2.58B | $2.50B |
| Revenue (TTM) | $2M | $51M | $0.00 | $416M | $236M |
| Net Income (TTM) | $-152M | $-315M | $-464M | $-2M | $-369M |
| Gross Margin | -6.3% | 33.2% | — | 90.9% | 90.7% |
| Operating Margin | -51.4% | -7.0% | — | 0.8% | -168.6% |
| Forward P/E | — | — | — | 77.6x | — |
| Total Debt | $13M | $82M | $98K | $6M | $99M |
| Cash & Equiv. | $125M | $357M | $714M | $43M | $222M |
RNAC vs KYMR vs IMVT vs ARQT vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNAC
KYMR
IMVT
ARQT
RCUS
| Stock | Aug 20 | May 26 | Return |
|---|---|---|---|
| Cartesian Therapeut… (RNAC) | 100 | 10.5 | -89.5% |
| Kymera Therapeutics… (KYMR) | 100 | 265.3 | +165.3% |
| Immunovant, Inc. (IMVT) | 100 | 80.2 | -19.8% |
| Arcutis Biotherapeu… (ARQT) | 100 | 82.4 | -17.6% |
| Arcus Biosciences, … (RCUS) | 100 | 104.2 | +4.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNAC vs KYMR vs IMVT vs ARQT vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ARQT leads in 2 of 6 categories (5-stock set), making it the strongest pick for growth and revenue expansion and operational efficiency and capital deployment. Kymera Therapeutics, Inc. is the stronger pick specifically for capital preservation and lower volatility. IMVT and RCUS also each lead in at least one category. As sector peers, any of these can serve as alternatives in the same allocation.
RNAC
Cartesian Therapeutics, Inc.
The Healthcare Pick
Among these 5 stocks, RNAC doesn't own a clear edge in any measured category.
Best for: healthcare exposure
KYMR
Kymera Therapeutics, Inc.
The Income Pick
KYMR is the #2 pick in this set and the best alternative if income & stability and defensive is your priority.
- beta 1.15
- Beta 1.15, current ratio 10.47x
- Beta 1.15 vs RNAC's 2.03
Best for: income & stability and defensive
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT ranks third and is worth considering specifically for long-term compounding and sleep-well-at-night.
- 173.6% 10Y total return vs KYMR's 154.4%
- Lower volatility, beta 1.37, Low D/E 0.0%, current ratio 11.16x
- 3.2% margin vs RNAC's -85.5%
Best for: long-term compounding and sleep-well-at-night
ARQT
Arcutis Biotherapeutics, Inc.
The Growth Play
ARQT carries the broadest edge in this set and is the clearest fit for growth exposure.
- Rev growth 91.3%, EPS growth 88.8%, 3Y rev CAGR 367.3%
- 91.3% revenue growth vs RNAC's -92.8%
- -0.6% ROA vs RNAC's -45.1%
Best for: growth exposure
RCUS
Arcus Biosciences, Inc.
The Momentum Pick
RCUS is the clearest fit if your priority is momentum.
- +209.6% vs RNAC's -19.6%
Best for: momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | ARQT | 91.3% revenue growth vs RNAC's -92.8% |
| Quality / Margins | IMVT | 3.2% margin vs RNAC's -85.5% |
| Stability / Safety | KYMR | Beta 1.15 vs RNAC's 2.03 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | RCUS | +209.6% vs RNAC's -19.6% |
| Efficiency (ROA) | ARQT | -0.6% ROA vs RNAC's -45.1% |
RNAC vs KYMR vs IMVT vs ARQT vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
Segment breakdown not available.
FY 2023
FY 2025
RNAC vs KYMR vs IMVT vs ARQT vs RCUS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLARQTLAGGINGRCUS
Who Leads Where
ARQT leads in 3 of 6 categories
KYMR leads 1 • RNAC leads 0 • IMVT leads 0 • RCUS leads 0 • 1 tied
Explore the data ↓RCUSArcus Biosciences, In…
0leads
IMVTImmunovant, Inc.
0leads
RNACCartesian Therapeutic…
0leads
KYMRKymera Therapeutics, …
1leads
ARQTArcutis Biotherapeuti…
3leads
6 Total Categories
CATEGORYLEADERvs KYMRvs RNACMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ARQT6/6
Valuation MetricsMultiples, price ratios, and targets
ARQT2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ARQT6/9
Total Returns1Y, 3Y, 5Y total returns with dividends
KYMR3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ARQT leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
ARQT and IMVT operate at a comparable scale, with $416M and $0 in trailing revenue. ARQT is the more profitable business, keeping -0.6% of every revenue dollar as net income compared to RNAC's -85.5%. On growth, ARQT holds the edge at +60.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $2M | $51M | $0 | $416M | $236M |
| EBITDAEarnings before interest/tax | -$90M | -$352M | -$487M | $6M | -$391M |
| Net IncomeAfter-tax profit | -$152M | -$315M | -$464M | -$2M | -$369M |
| Free Cash FlowCash after capex | -$77M | -$244M | -$423M | $27M | -$489M |
| Gross MarginGross profit ÷ Revenue | -6.3% | +33.2% | — | +90.9% | +90.7% |
| Operating MarginEBIT ÷ Revenue | -51.4% | -7.0% | — | +0.8% | -168.6% |
| Net MarginNet income ÷ Revenue | -85.5% | -6.1% | — | -0.6% | -156.4% |
| FCF MarginFCF ÷ Revenue | -43.6% | -4.7% | — | +6.5% | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | -92.9% | +55.5% | — | +60.1% | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | -114.7% | +13.4% | +19.7% | +55.0% | +10.5% |
ARQT leads this category, winning 6 of 6 comparable metrics.
Valuation Metrics
ARQT leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| Market CapShares × price | $216M | $6.9B | $5.5B | $2.6B | $2.5B |
| Enterprise ValueMkt cap + debt − cash | $104M | $6.6B | $4.8B | $2.5B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -1.63x | -22.93x | -9.97x | -158.92x | -7.54x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | 77.64x | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 77.34x | 176.26x | — | 6.87x | 10.11x |
| Price / BookPrice ÷ Book value/share | — | 4.52x | 5.83x | 13.87x | 4.22x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
ARQT leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
ARQT leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
ARQT delivers a -1.4% return on equity — every $100 of shareholder capital generates $-1 in annual profit, vs $-69 for RCUS. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), KYMR scores 4/9 vs RCUS's 0/9, reflecting mixed financial health.
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | — | -25.0% | -47.1% | -1.4% | -69.0% |
| ROA (TTM)Return on assets | -45.1% | -22.3% | -44.1% | -0.6% | -35.3% |
| ROICReturn on invested capital | — | -24.9% | — | -5.2% | -64.1% |
| ROCEReturn on capital employed | -25.0% | -27.2% | -66.1% | -4.3% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 4 | 2 | 4 | 0 |
| Debt / EquityFinancial leverage | — | 0.05x | 0.00x | 0.03x | 0.16x |
| Net DebtTotal debt minus cash | -$112M | -$275M | -$714M | -$37M | -$123M |
| Cash & Equiv.Liquid assets | $125M | $357M | $714M | $43M | $222M |
| Total DebtShort + long-term debt | $13M | $82M | $98,000 | $6M | $99M |
| Interest CoverageEBIT ÷ Interest expense | — | -2119.53x | — | 2.08x | -13.38x |
ARQT leads this category, winning 6 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
KYMR leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in KYMR five years ago would be worth $19,212 today (with dividends reinvested), compared to $875 for RNAC. Over the past 12 months, RCUS leads with a +209.6% total return vs RNAC's -19.6%. The 3-year compound annual growth rate (CAGR) favors KYMR at 45.0% vs RNAC's -38.9% — a key indicator of consistent wealth creation.
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +20.7% | +16.3% | +5.1% | -28.8% | +6.5% |
| 1-Year ReturnPast 12 months | -19.6% | +190.7% | +96.1% | +50.8% | +209.6% |
| 3-Year ReturnCumulative with dividends | -77.1% | +205.1% | +40.9% | +44.9% | +24.9% |
| 5-Year ReturnCumulative with dividends | -91.3% | +92.1% | +62.4% | -39.5% | -18.6% |
| 10-Year ReturnCumulative with dividends | -98.1% | +154.4% | +173.6% | -5.2% | +45.9% |
| CAGR (3Y)Annualised 3-year return | -38.9% | +45.0% | +12.1% | +13.2% | +7.7% |
KYMR leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — KYMR and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
KYMR is the less volatile stock with a 1.15 beta — it tends to amplify market swings less than RNAC's 2.03 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs RNAC's 52.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.03x | 1.15x | 1.37x | 1.48x | 1.95x |
| 52-Week HighHighest price in past year | $15.57 | $103.00 | $30.09 | $31.77 | $28.72 |
| 52-Week LowLowest price in past year | $5.60 | $28.06 | $13.36 | $12.42 | $7.06 |
| % of 52W HighCurrent price vs 52-week peak | +52.4% | +82.2% | +90.5% | +65.0% | +86.3% |
| RSI (14)Momentum oscillator 0–100 | 68.7 | 54.1 | 60.2 | 54.3 | 60.5 |
| Avg Volume (50D)Average daily shares traded | 225K | 602K | 1.4M | 1.3M | 1.2M |
Evenly matched — KYMR and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RNAC as "Buy", KYMR as "Buy", IMVT as "Buy", ARQT as "Buy", RCUS as "Buy". Consensus price targets imply 96.1% upside for RNAC (target: $16) vs 21.0% for RCUS (target: $30).
| Metric | RNACCartesian Therape… | KYMRKymera Therapeuti… | IMVTImmunovant, Inc. | ARQTArcutis Biotherap… | RCUSArcus Biosciences… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $16.00 | $117.06 | $45.50 | $35.50 | $30.00 |
| # AnalystsCovering analysts | 10 | 26 | 23 | 12 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ARQT leads in 3 of 6 categories (Income & Cash Flow, Valuation Metrics). KYMR leads in 1 (Total Returns). 1 tied.
Best OverallArcutis Biotherapeutics, In… (ARQT)Leads 3 of 6 categories
Loading custom metrics...
RNAC vs KYMR vs IMVT vs ARQT vs RCUS: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is RNAC or KYMR or IMVT or ARQT or RCUS a better buy right now?
For growth investors, Arcutis Biotherapeutics, Inc.
(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). Analysts rate Cartesian Therapeutics, Inc. (RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — RNAC or KYMR or IMVT or ARQT or RCUS?
Over the past 5 years, Kymera Therapeutics, Inc.
(KYMR) delivered a total return of +92. 1%, compared to -91. 3% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus RNAC's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — RNAC or KYMR or IMVT or ARQT or RCUS?
By beta (market sensitivity over 5 years), Kymera Therapeutics, Inc.
(KYMR) is the lower-risk stock at 1. 15β versus Cartesian Therapeutics, Inc. 's 2. 03β — meaning RNAC is approximately 76% more volatile than KYMR relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — RNAC or KYMR or IMVT or ARQT or RCUS?
By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.
(ARQT) is pulling ahead at 91. 3% versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -52. 6% for Cartesian Therapeutics, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — RNAC or KYMR or IMVT or ARQT or RCUS?
Immunovant, Inc.
(IMVT) is the more profitable company, earning 0. 0% net margin versus -46. 6% for Cartesian Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: IMVT leads at 0. 0% versus -31. 0% for RNAC. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is RNAC or KYMR or IMVT or ARQT or RCUS more undervalued right now?
Analyst consensus price targets imply the most upside for RNAC: 96.
1% to $16. 00.
07Which pays a better dividend — RNAC or KYMR or IMVT or ARQT or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is RNAC or KYMR or IMVT or ARQT or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Kymera Therapeutics, Inc.
(KYMR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 15), +154. 4% 10Y return). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KYMR: +154. 4%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between RNAC and KYMR and IMVT and ARQT and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RNAC is a small-cap quality compounder stock; KYMR is a small-cap quality compounder stock; IMVT is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; RCUS is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(RNAC: -92.9% · KYMR: 55.5%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.